Proteomic analysis of serum for identification of potential biomarkers predicting response of patients with refractory multiple myeloma to bortezomib‑based therapy

Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis

“…The development of new biomarkers predicting response to therapy would allow an identification of patients who should receive other first -line therapeutic regimens as the first -line treatment. [18][19][20] As in the previous reports, impaired renal function did not have negative impact on the response rates or PFS. Importantly, patients who responded to therapy showed an improvement in renal function, confirming the efficacy of this protocol in patients with renal failure.…”